| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $20.3M | +41.3% |
| SG&A Expense | $4.2M | +116.3% |
| Operating Income | -$24.5M | -50.2% |
| Pre-tax Income | $23.5M | +37.7% |
| Net Income | -$23.5M | -37.7% |
| EPS (Basic) | -$0.75 | +77.3% |
| EPS (Diluted) | -$0.75 | +77.3% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $13.2M | -53.5% |
| Short-term Investments | $11.2M | — |
| Current Assets | $27.3M | -6.8% |
| Total Assets | $30.8M | +5.4% |
| Current Liabilities | $9.5M | +272.3% |
| Total Liabilities | $9.5M | +73.0% |
| Stockholders' Equity | $21.3M | -10.3% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$22.8M | -89.2% |
| Investing Cash Flow | -$10.9M | — |
| Financing Cash Flow | $18.5M | -53.4% |